Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are gathering real-world data from patients with Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase Ph-CML-CP who are treated with tyrosine kinase inhibitors TKIs approved for first or second line therapy. This registry study aims to collect evidence on the tolerability, safety, effectiveness, and patient-reported outcomes over a prospective follow-up period of 5 years to understand long-term treatment results in routine healthcare settings. Participants will be those receiving TKI treatments including asciminib, bosutinib, dasatinib, imatinib, or nilotinib as prescribed in standard medical care, either as initial therapy or after one prior TKI therapy. The study includes patients who began these treatments on or after specified dates and those continuing asciminib after participating in an interventional trial. There is no treatment allocation instead, patients are observed based on their current prescribed TKI therapy. During the 5-year follow-up, participants treatment continuation and discontinuation due to adverse events will be monitored, along with the occurrence of adverse events, treatment switches, molecular and hematological responses, survival outcomes, and patient-reported measures of health, symptoms, and medication adherence. Data will be collected from electronic medical records and claims data with patient consent, ensuring ongoing safety and effectiveness observations in real-world care up to 5 years.
Actively Recruiting
Researchers are evaluating the safety, how the body processes, and how well the study medicine nirmatrelvirritonavir works for treating COVID-19 in children under 18 years old who are not hospitalized but at risk of severe illness. This trial is a Phase 3, open-label study focusing on nonhospitalized pediatric patients with COVID-19 to better understand the effects of this oral medication. The study medicine is given by mouth as tablets or powder twice daily for 5 days, totaling 10 doses. Different dosing forms and amounts are used depending on the participants age and weight, ranging from under 1 month old up to 18 years. Participants are assigned to one of several groups based on these factors to receive the medicine accordingly. During the study, participants will have blood samples taken to measure drug levels at specific times, and researchers will monitor for any side effects or changes in vital signs up to 34 days after starting treatment. They will also measure viral load through nasal swabs at several points over 28 days and assess hospitalizations or deaths related to COVID-19. Participants feedback on the medicines taste and acceptability will be collected during treatment.
Actively Recruiting
Healthy Volunteer
This research aims to improve weight management counseling WMC skills among medical residents, addressing the lack of such training during residency. It evaluates how effective the MRWeight curriculum is in enhancing residents WMC skills, their use of these skills with patients, and the best ways to encourage adoption. The study is a group randomized controlled trial involving eight Internal Medicine residency programs and follows three cohorts of first-year residents over 18 months. The study compares two groups of residents one receiving a core foundational course on WMC, and the other receiving an enhanced MRWeight intervention. The intervention includes two 45-minute didactic sessions, a series of six email modules with video-based communication practice, and email reinforcements over 12 months. The comparison group receives only the foundational course slides. Both groups complete three assessments during the 18-month period to evaluate their WMC skills and adoption. Participants take part in surveys and video communication assessments at baseline, around 9-12 months, and at 18 months. The study measures changes in WMC skills and the adoption of these skills in clinical practice. Researchers monitor the results to understand the interventions impact, with the primary assessment focusing on skill changes at 12 months and adoption at 18 months. The total participation duration spans 18 months, with evaluations designed to track progress over time.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are conducting an international retrospective and prospective study to better understand hyposplasminogenemia, a condition caused by plasminogen deficiency. This study aims to define the natural history of the disease, explore the variability in how it presents in different people, identify markers that predict disease progression, and help develop improved treatments. The research is being conducted across two main centers in the Americas and Europe, gathering data from affected individuals and their first-degree family members. The study will collect both retrospective data from the past year and prospective data for three years on approximately 100 affected individuals and about 500 family members. Biological samples such as DNA and plasma will be collected and analyzed centrally in Italy, except for urine samples that will be analyzed locally. The study will test plasminogen activity and antigen levels, genetic mutations, and other factors influencing disease expression. Follow-up will include in-person visits at the start and end of the study, with telephone check-ins every six months and unscheduled visits as needed based on clinical care. Participants will be involved in providing samples and clinical information at baseline and at the end of their three-year study period. The researchers will monitor disease progression and gather data through regular telephone follow-ups and clinical visits. The main outcomes measured include the natural history of plasminogen deficiency, factors influencing disease severity, and the creation of a biobank for future research. The study is designed to improve understanding of this rare condition over a long-term observation period.